CDK9-IN-14

CDK9-IN-14 is a potent and selective CDK9 inhibitor with IC50 of 6.92 nM. CDK9-IN-14 has a relatively strong inhibitory effect on MV4;11 cells and in vivo tumor models, and has a good selectivity and a low toxicity and few side effects[1].

Research Areas >> Cancer

Signaling Pathways >> Cell Cycle/DNA Damage >> CDK

CDK9:6.92 nM (IC50)

CDK9-IN-14 (0-1000 nM) has strong inhibitory effect in MV4;11 cells with IC50 = 34 nM[1].

CDK9-IN-14 (5 mg/kg; p.o., qd, for 9 days) exhibits significant anti-tumor effect with tumor growth inhibition (TGI) value of 58%[1]. Animal Model: Female Nu/Nu mice (6-8 weeks old, 18-22 g, injected with HL-60 cells)[1] Dosage: 5 mg/kg Administration: p.o., qd, for 9 days Result: Exhibited significant anti-tumor effect with tumor growth inhibition (TGI) value of 58%.

[1]. WANG Zhenyu. Compound as cyclin-dependent kinase 9 inhibitor and use thereof. WO2021115335A1